YOU WONT BELIEVE: Kukbo | Mind Blowing Facts

RedHill Biopharma Ltd's (NASDAQ:RDHL) opaganib (ABC294640), an oral drug candidate for hospitalized COVID-19 patients, demonstrated potent in vitro efficacy against the omicron variant while maintaining host cell viability.  The Company says that based on the new and previously announced data, opaganib's dual antiviral and anti-inflammatory suggested mechanism is expected to act independently of…